INM News and Press, InMed Pharmaceuticals Inc.

Vancouver, British Columbia--(Newsfile Corp. - February 11, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical ne...

2026-02-10 17:39:20 ET InMed Pharmaceuticals Inc. (INM) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 4.59%. The average open to low on the day of earnings was -4.90%. The average open...

2026-02-10 17:34:22 ET InMed Pharmaceuticals Inc. (INM) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in INM stock price following earnings has averaged ±1.87% , with a median of 0.97%....

2025-12-17 20:59:04 ET InMed Pharmaceuticals Inc. (INM) Shareholder/Analyst Call December 17, 2025 7:01 PM EST... Read the full article on Seeking Alpha For further details see: InMed Pharmaceuticals Inc. (INM) Shareholder/Analyst Call Prepared Remarks Transcript

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (" InMed " or the " Company "), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today co...

Vancouver, British Columbia--(Newsfile Corp. - December 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (" InMed " or the " Company "), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today ...

NEW YORK, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, announced the agenda for the Life Sciences Virtual Investor Forum to be held December 11 th . Individual investors, institutional investors, advisors, and analysts...

Data demonstrate a favorable bioavailability profile of INM-901 oral formulation Data will support design and planning of first in human clinical trials Preparing for pre-IND meeting with the FDA Vancouver, British Columbia--(Newsfile Corp. - November 18, 2025) - InMed Pharmaceuticals I...

2025-11-06 17:57:57 ET More on InMed Pharmaceuticals Seeking Alpha’s Quant Rating on InMed Pharmaceuticals Financial information for InMed Pharmaceuticals Read the full article on Seeking Alpha For further details see: InMed Pharmaceuticals GAAP EP...

Vancouver, British Columbia--(Newsfile Corp. - November 6, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical nee...